Richard Weinshilboum, MD, has established a research program at the Mayo Clinic that uses genomic techniques, including genomewide association studies and whole genome DNA sequencing, which uses samples from large numbers of patients treated with a specific anticancer or antidepressant drug. He sat down with Federal Practitioner to discuss the role genetic testing plays in personalized medicine.
Individualized therapy: 1:11
Common genetic variations: 2:41
Using genomics for preemptive treatment: 6:06
Privacy concerns: 7:44
Cost effectiveness: 8:43
Applying genomics: 10:06